January 30, 2012 — Medtronic, Inc. announced the completion of patient enrollment in the extreme risk study in its CoreValve United States Pivotal Trial. The company received approval from the U.S. Food and Drug Administration (FDA) for an extended investigation (under the FDA’s Continued Access Policy) to continue enrolling extreme risk patients under a Continued Access Study protocol.
